# Marco Rovaris

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 270 papers | 12,202 citations | 62 h-index | 99 g-index |
| 277 ext. papers | 13,354 ext. citations | 5.4 avg, IF | 5.6 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 270 | Physical activity in non-disabled People with early Multiple Sclerosis: a multicenter cross-sectional study. *Multiple Sclerosis and Related Disorders*, **2022**, 103941 | 4 | 0 |
| 269 | Walking With Horizontal Head Turns Is Impaired in Persons With Early-Stage Multiple Sclerosis Showing Normal Locomotion.. *Frontiers in Neurology*, **2021**, 12, 821640 | 4.1 | 1 |
| 268 | Prevalence and patterns of subclinical motor and cognitive impairments in non-disabled individuals with early multiple sclerosis: A multicenter cross-sectional study. *Annals of Physical and Rehabilitation Medicine*, **2021**, 65, 101491 | 3.8 | 5 |
| 267 | Effects of home-based virtual reality telerehabilitation system in people with multiple sclerosis: A randomized controlled trial. *Journal of Telemedicine and Telecare*, **2021**, 1357633X211054839 | 6.8 | 1 |
| 266 | Neuroplasticity and Motor Rehabilitation in Multiple Sclerosis: A Systematic Review on MRI Markers of Functional and Structural Changes. *Frontiers in Neuroscience*, **2021**, 15, 707675 | 5.1 | 2 |
| 265 | Effects of voice rehabilitation in people with MS: A double-blinded long-term randomized controlled trial. *Multiple Sclerosis Journal*, **2021**, 13524585211051059 | 5 | 0 |
| 264 | Social Cognition Training for Enhancing Affective and Cognitive Theory of Mind in Schizophrenia: A Systematic Review and a Meta-Analysis. *Journal of Psychology: Interdisciplinary and Applied*, **2021**, 155, 26-58 | 2.7 | 6 |
| 263 | Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors. *Multiple Sclerosis Journal*, **2021**, 27, 430-438 | 5 | 1 |
| 262 | The IN-DEEP project "INtegrating and Deriving Evidence, Experiences, Preferences": a web information model on magnetic resonance imaging for people with multiple sclerosis. *Journal of Neurology*, **2020**, 267, 2421-2431 | 5.5 | 1 |
| 261 | Assessing balance in non-disabled subjects with multiple sclerosis: Validation of the Fullerton Advanced Balance Scale. *Multiple Sclerosis and Related Disorders*, **2020**, 42, 102085 | 4 | 5 |
| 260 | Impaired heart rate recovery after sub-maximal physical exercise in people with multiple sclerosis. *Multiple Sclerosis and Related Disorders*, **2020**, 40, 101960 | 4 | 0 |
| 259 | Italian consensus on treatment of spasticity in multiple sclerosis. *European Journal of Neurology*, **2020**, 27, 445-453 | 6 | 9 |
| 258 | Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2020**, 91, 914-920 | 5.5 | 1 |
| 257 | Improved Gait of Persons With Multiple Sclerosis After Rehabilitation: Effects on Lower Limb Muscle Synergies, Push-Off, and Toe-Clearance. *Frontiers in Neurology*, **2020**, 11, 668 | 4.1 | 2 |
| 256 | Mindfulness-Based Interventions for the Improvement of Well-Being in People With Multiple Sclerosis: A Systematic Review and Meta-Analysis. *Psychosomatic Medicine*, **2020**, 82, 600-613 | 3.7 | 7 |
| 255 | Integrated telerehabilitation approach in multiple sclerosis: A systematic review and meta-analysis. *Journal of Telemedicine and Telecare*, **2020**, 26, 385-399 | 6.8 | 29 |
| 254 | Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register. *Journal of Neurology*, **2019**, 266, 3098-3107 | 5.5 | 1 |

| | | | |
|---|---|---|---|
| 253 | Acute Fingolimod Effects on Baroreflex and Cardiovascular Autonomic Control in Multiple Sclerosis. *Journal of Central Nervous System Disease*, **2019**, 11, 1179573519849945 | 4.4 | 4 |
| 252 | A Deficit of CEACAM-1-Expressing T Lymphocytes Supports Inflammation in Primary Progressive Multiple Sclerosis. *Journal of Immunology*, **2019**, 203, 76-83 | 5.3 | 6 |
| 251 | Predictors of hospital-based multidisciplinary rehabilitation effects in persons with multiple sclerosis: a large-scale, single-centre study. *Multiple Sclerosis Journal - Experimental, Translational and Clinical*, **2019**, 5, 2055217319843673 | 2 | 1 |
| 250 | The Effects of Transcutaneous Spinal Direct Current Stimulation on Neuropathic Pain in Multiple Sclerosis: Clinical and Neurophysiological Assessment. *Frontiers in Human Neuroscience*, **2019**, 13, 31 | 3.3 | 11 |
| 249 | Effect of arm cycling and task-oriented exercises on fatigue and upper limb performance in multiple sclerosis: a randomized crossover study. *International Journal of Rehabilitation Research*, **2019**, 42, 300-308 | 1.8 | 4 |
| 248 | A simple and universal enzyme-free approach for the detection of multiple microRNAs using a single nanostructured enhancer of surface plasmon resonance imaging. *Analytical and Bioanalytical Chemistry*, **2019**, 411, 1873-1885 | 4.4 | 23 |
| 247 | The Italian multiple sclerosis register. *Neurological Sciences*, **2019**, 40, 155-165 | 3.5 | 42 |
| 246 | Longitudinal associations between mindfulness and well-being in people with multiple sclerosis. *International Journal of Clinical and Health Psychology*, **2019**, 19, 22-30 | 5.1 | 28 |
| 245 | Online meditation training for people with multiple sclerosis: A randomized controlled trial. *Multiple Sclerosis Journal*, **2019**, 25, 610-617 | 5 | 30 |
| 244 | Effects of motor rehabilitation on mobility and brain plasticity in multiple sclerosis: a structural and functional MRI study. *Journal of Neurology*, **2018**, 265, 1393-1401 | 5.5 | 40 |
| 243 | HLA alleles modulate EBV viral load in multiple sclerosis. *Journal of Translational Medicine*, **2018**, 16, 80 | 8.5 | 20 |
| 242 | Prediction of Falls in Subjects Suffering From Parkinson Disease, Multiple Sclerosis, and Stroke. *Archives of Physical Medicine and Rehabilitation*, **2018**, 99, 641-651 | 2.8 | 27 |
| 241 | Response to Letter "Prediction of Falls in Subjects Suffering From Parkinson Disease, Multiple Sclerosis, and Stroke: Methodologic Issues". *Archives of Physical Medicine and Rehabilitation*, **2018**, 99, 1688-1689 | 2.8 | 0 |
| 240 | Monosodium Urate Crystals Activate the Inflammasome in Primary Progressive Multiple Sclerosis. *Frontiers in Immunology*, **2018**, 9, 983 | 8.4 | 21 |
| 239 | Intensive Multimodal Training to Improve Gait Resistance, Mobility, Balance and Cognitive Function in Persons With Multiple Sclerosis: A Pilot Randomized Controlled Trial. *Frontiers in Neurology*, **2018**, 9, 800 | 4.1 | 23 |
| 238 | Two-year real-life efficacy, tolerability and safety of dimethyl fumarate in an Italian multicentre study. *Journal of Neurology*, **2018**, 265, 1850-1859 | 5.5 | 27 |
| 237 | Cardiac autonomic function during postural changes and exercise in people with multiple sclerosis: A cross-sectional study. *Multiple Sclerosis and Related Disorders*, **2018**, 24, 85-90 | 4 | 2 |
| 236 | White Matter Tract Injury is Associated with Deep Gray Matter Iron Deposition in Multiple Sclerosis. *Journal of Neuroimaging*, **2017**, 27, 107-113 | 2.8 | 15 |

| | | | |
|---|---|---|---|
| 235 | Indoleamine-2,3-dioxygenase(IDO)2 polymorphisms are not associated with multiple sclerosis in Italians. *Journal of the Neurological Sciences*, **2017**, 377, 31-34 | 3.2 | 5 |
| 234 | Long-term disability progression in primary progressive multiple sclerosis: a 15-year study. *Brain*, **2017**, 140, 2814-2819 | 11.2 | 38 |
| 233 | Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study). *PLoS ONE*, **2017**, 12, e0180651 | 3.7 | 20 |
| 232 | The still under-investigated role of cognitive deficits in PML diagnosis. *Multiple Sclerosis and Demyelinating Disorders*, **2017**, 2, | 0 | 3 |
| 231 | Multidisciplinary Rehabilitation is Efficacious and Induces Neural Plasticity in Multiple Sclerosis even when Complicated by Progressive Multifocal Leukoencephalopathy. *Frontiers in Neurology*, **2017**, 8, 491 | 4.1 | 1 |
| 230 | Fingolimod effects on left ventricular function in multiple sclerosis. *Multiple Sclerosis Journal*, **2016**, 22, 201-11 | 5 | 19 |
| 229 | Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. *The Cochrane Library*, **2016**, 11, CD009333 | 5.2 | 25 |
| 228 | 6-Month Effects of Fingolimod on Indexes of Cardiovascular Autonomic Control in Multiple Sclerosis. *Journal of the American College of Cardiology*, **2016**, 68, 2027-2029 | 15.1 | 5 |
| 227 | A semi-automated measuring system of brain diffusion and perfusion magnetic resonance imaging abnormalities in patients with multiple sclerosis based on the integration of coregistration and tissue segmentation procedures. *BMC Medical Imaging*, **2016**, 16, 4 | 2.9 | 3 |
| 226 | Response to letter regarding article ‘Fingolimod effects on left ventricular function in multiple sclerosis’*Multiple Sclerosis Journal*, **2016**, 22, 708-9 | 5 | |
| 225 | A telemedicine meditation intervention for people with multiple sclerosis and their caregivers: study protocol for a randomized controlled trial. *Trials*, **2016**, 17, 4 | 2.8 | 11 |
| 224 | Diagnostic tools for assessment of urinary dysfunction in MS patients without urinary disturbances. *Neurological Sciences*, **2016**, 37, 437-42 | 3.5 | 2 |
| 223 | Are Modular Activations Altered in Lower Limb Muscles of Persons with Multiple Sclerosis during Walking? Evidence from Muscle Synergies and Biomechanical Analysis. *Frontiers in Human Neuroscience*, **2016**, 10, 620 | 3.3 | 29 |
| 222 | Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, 944-51 | 5.5 | 63 |
| 221 | B Lymphocytes in Multiple Sclerosis: Bregs and BTLA/CD272 Expressing-CD19+ Lymphocytes Modulate Disease Severity. *Scientific Reports*, **2016**, 6, 29699 | 4.9 | 28 |
| 220 | Grey matter damage in progressive multiple sclerosis versus amyotrophic lateral sclerosis: a voxel-based morphometry MRI study. *Neurological Sciences*, **2015**, 36, 371-7 | 3.5 | 11 |
| 219 | Modular organization of lower limbs in persons with multiple sclerosis and healthy persons during walking. *Gait and Posture*, **2015**, 42, S14-S15 | 2.6 | 1 |
| 218 | MicroRNA-572 expression in multiple sclerosis patients with different patterns of clinical progression. *Journal of Translational Medicine*, **2015**, 13, 148 | 8.5 | 29 |

| | | | |
|---|---|---|---|
| 217 | Corticospinal tract integrity is related to primary motor cortex thinning in relapsing-remitting multiple sclerosis. *Multiple Sclerosis Journal*, **2015**, 21, 1771-80 | 5 | 29 |
| 216 | Comparative efficacy of interferon versus glatiramer acetate for relapsing-remitting multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2015**, 86, 1016-20 | 5.5 | 12 |
| 215 | Indoleamine 2,3 Dioxygenase (IDO) Expression and Activity in Relapsing-Remitting Multiple Sclerosis. *PLoS ONE*, **2015**, 10, e0130715 | 3.7 | 55 |
| 214 | Predictors of effectiveness of multidisciplinary rehabilitation treatment on motor dysfunction in multiple sclerosis. *Multiple Sclerosis Journal*, **2014**, 20, 862-70 | 5 | 9 |
| 213 | Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. *Cochrane Database of Systematic Reviews*, **2014**, CD009333 | | 16 |
| 212 | Drug therapy for multiple sclerosis. *Cmaj*, **2014**, 186, 833-40 | 3.5 | 15 |
| 211 | Insights from magnetic resonance imaging. *Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn*, **2014**, 122, 115-49 | 3 | 18 |
| 210 | Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. *BMC Neurology*, **2014**, 14, 65 | 3.1 | 43 |
| 209 | Toll-like receptor 3 differently modulates inflammation in progressive or benign multiple sclerosis. *Clinical Immunology*, **2014**, 150, 109-20 | 9 | 11 |
| 208 | A role for the TIM-3/GAL-9/BAT3 pathway in determining the clinical phenotype of multiple sclerosis. *FASEB Journal*, **2014**, 28, 5000-9 | 0.9 | 23 |
| 207 | Determinants of disability in multiple sclerosis: an immunological and MRI study. *BioMed Research International*, **2014**, 2014, 875768 | 3 | 12 |
| 206 | Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration. *Multiple Sclerosis Journal*, **2014**, 20, 72-80 | 5 | 81 |
| 205 | The Peripheral Network between Oxidative Stress and Inflammation in Multiple Sclerosis. *European Journal of Inflammation*, **2014**, 12, 351-363 | 0.3 | 3 |
| 204 | Effects of natalizumab on oligoclonal bands in the cerebrospinal fluid of multiple sclerosis patients: a longitudinal study. *Multiple Sclerosis Journal*, **2014**, 20, 1900-3 | 5 | 39 |
| 203 | Oxidative stress is differentially present in multiple sclerosis courses, early evident, and unrelated to treatment. *Journal of Immunology Research*, **2014**, 2014, 961863 | 4.5 | 39 |
| 202 | A novel data mining system points out hidden relationships between immunological markers in multiple sclerosis. *Immunity and Ageing*, **2013**, 10, 1 | 9.7 | 20 |
| 201 | Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis. *Journal of Neurology*, **2013**, 260, 2458-71 | 5.5 | 83 |
| 200 | Mitoxantrone for multiple sclerosis. *The Cochrane Library*, **2013**, CD002127 | 5.2 | 46 |

| | | | |
|---|---|---|---|
| 199 | T helper-17 activation dominates the immunologic milieu of both amyotrophic lateral sclerosis and progressive multiple sclerosis. *Clinical Immunology*, **2013**, 148, 79-88 | 9 | 44 |
| 198 | Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of 462 cases. *Neurological Sciences*, **2013**, 34, 1633-7 | 3.5 | 17 |
| 197 | Interferon β for secondary progressive multiple sclerosis: a systematic review. *Journal of Neurology, Neurosurgery and Psychiatry*, **2013**, 84, 420-6 | 5.5 | 38 |
| 196 | Adverse events after endovascular treatment of chronic cerebro-spinal venous insufficiency (CCSVI) in patients with multiple sclerosis. *Multiple Sclerosis Journal*, **2013**, 19, 961-3 | 5 | 14 |
| 195 | TH17-Driven Inflammation is Present in All Clinical Forms of Multiple Sclerosis; Disease Quiescence is Associated with Gata3-Expressing Cells. *European Journal of Inflammation*, **2013**, 11, 223-235 | 0.3 | 6 |
| 194 | Atlas-based versus individual-based fiber tracking of the corpus callosum in patients with multiple sclerosis: reliability and clinical correlations. *Journal of Neuroimaging*, **2012**, 22, 355-64 | 2.8 | 4 |
| 193 | JC virus detection and JC virus-specific immunity in natalizumab-treated multiple sclerosis patients. *Journal of Translational Medicine*, **2012**, 10, 248 | 8.5 | 16 |
| 192 | Interferon beta for secondary progressive multiple sclerosis. *The Cochrane Library*, **2012**, 1, CD005181 | 5.2 | 41 |
| 191 | Signal-to-noise ratio of diffusion weighted magnetic resonance imaging: Estimation methods and in vivo application to spinal cord. *Biomedical Signal Processing and Control*, **2012**, 7, 285-294 | 4.9 | 7 |
| 190 | Assessment of disease activity in multiple sclerosis phenotypes with combined gadolinium- and superparamagnetic iron oxide-enhanced MR imaging. *Radiology*, **2012**, 264, 225-33 | 20.5 | 65 |
| 189 | Modulation of the central memory and Tr1-like regulatory T cells in multiple sclerosis patients responsive to interferon-beta therapy. *Multiple Sclerosis Journal*, **2012**, 18, 788-98 | 5 | 15 |
| 188 | T2 lesion location really matters: a 10 year follow-up study in primary progressive multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2011**, 82, 72-7 | 5.5 | 41 |
| 187 | Opposite effects of interferon-β on new B and T cell release from production sites in multiple sclerosis patients. *Journal of Neuroimmunology*, **2011**, 240-241, 147-50 | 3.5 | 13 |
| 186 | Relationship between brain MRI lesion load and short-term disease evolution in non-disabling MS: a large-scale, multicentre study. *Multiple Sclerosis Journal*, **2011**, 17, 319-26 | 5 | 8 |
| 185 | MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials. *Nature Reviews Neurology*, **2011**, 8, 13-21 | 15 | 57 |
| 184 | A diffusion tensor MRI study of cervical cord damage in benign and secondary progressive multiple sclerosis patients. *Journal of Neurology, Neurosurgery and Psychiatry*, **2010**, 81, 26-30 | 5.5 | 34 |
| 183 | Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. *Neurology*, **2010**, 74, 1868-76 | 6.5 | 234 |
| 182 | MRI criteria for MS in patients with clinically isolated syndromes. *Neurology*, **2010**, 74, 427-34 | 6.5 | 187 |

| | | | |
|---|---|---|---|
| 181 | DTI parameter optimisation for acquisition at 1.5T: SNR analysis and clinical application. *Computational Intelligence and Neuroscience*, **2010**, 254032 | 3 | 21 |
| 180 | Intercenter differences in diffusion tensor MRI acquisition. *Journal of Magnetic Resonance Imaging*, **2010**, 31, 1458-68 | 5.6 | 66 |
| 179 | Costimulatory pathways in multiple sclerosis: distinctive expression of PD-1 and PD-L1 in patients with different patterns of disease. *Journal of Immunology*, **2009**, 183, 4984-93 | 5.3 | 66 |
| 178 | Atlas-based vs. individual-based deterministic tractography of corpus callosum in multiple sclerosis. *Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference*, **2009**, 2009, 2699-702 | 0.9 | 1 |
| 177 | Primary progressive multiple sclerosis diagnostic criteria: a reappraisal. *Multiple Sclerosis Journal*, **2009**, 15, 1459-65 | 5 | 26 |
| 176 | A reassessment of the plateauing relationship between T2 lesion load and disability in MS. *Neurology*, **2009**, 73, 1538-42 | 6.5 | 32 |
| 175 | Evidence for relative cortical sparing in benign multiple sclerosis: a longitudinal magnetic resonance imaging study. *Multiple Sclerosis Journal*, **2009**, 15, 36-41 | 5 | 64 |
| 174 | A single, early magnetic resonance imaging study in the diagnosis of multiple sclerosis. *Archives of Neurology*, **2009**, 66, 587-92 | | 96 |
| 173 | In-vivo evidence for stable neuroaxonal damage in the brain of patients with benign multiple sclerosis. *Multiple Sclerosis Journal*, **2009**, 15, 789-94 | 5 | 21 |
| 172 | Can rate of brain atrophy in multiple sclerosis be explained by clinical and MRI characteristics?. *Multiple Sclerosis Journal*, **2009**, 15, 465-71 | 5 | 13 |
| 171 | MRI features of benign multiple sclerosis: toward a new definition of this disease phenotype. *Neurology*, **2009**, 72, 1693-701 | 6.5 | 43 |
| 170 | Corpus callosum damage and cognitive dysfunction in benign MS. *Human Brain Mapping*, **2009**, 30, 2656-66 | 5.9 | 82 |
| 169 | Diffusion tensor MR imaging. *Neuroimaging Clinics of North America*, **2009**, 19, 37-43 | 3 | 63 |
| 168 | Morphology and evolution of cortical lesions in multiple sclerosis. A longitudinal MRI study. *NeuroImage*, **2008**, 42, 1324-8 | 7.9 | 51 |
| 167 | Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. *Lancet, The*, **2008**, 371, 2085-92 | 40 | 236 |
| 166 | Cognitive impairment and structural brain damage in benign multiple sclerosis. *Neurology*, **2008**, 71, 1521-6 | 6.5 | 79 |
| 165 | Absence of diffuse cervical cord tissue damage in early, non-disabling relapsing-remitting MS: a preliminary study. *Multiple Sclerosis Journal*, **2008**, 14, 853-6 | 5 | 13 |
| 164 | Large-scale, multicentre, quantitative MRI study of brain and cord damage in primary progressive multiple sclerosis. *Multiple Sclerosis Journal*, **2008**, 14, 455-64 | 5 | 46 |

| | | | |
|---|---|---|---|
| 163 | A magnetic resonance imaging voxel-based morphometry study of regional gray matter atrophy in patients with benign multiple sclerosis. *Archives of Neurology*, **2008**, 65, 1223-30 | | 54 |
| 162 | The definition of non-responder to multiple sclerosis treatment: neuroimaging markers. *Neurological Sciences*, **2008**, 29 Suppl 2, S222-4 | 3.5 | 3 |
| 161 | MRI characteristics of atypical idiopathic inflammatory demyelinating lesions of the brain : A review of reported findings. *Journal of Neurology*, **2008**, 255, 1-10 | 5.5 | 63 |
| 160 | A 3-year diffusion tensor MRI study of grey matter damage progression during the earliest clinical stage of MS. *Journal of Neurology*, **2008**, 255, 1209-14 | 5.5 | 34 |
| 159 | Agreement between different input image types in brain atrophy measurement in multiple sclerosis using SIENAX and SIENA. *Journal of Magnetic Resonance Imaging*, **2008**, 28, 559-65 | 5.6 | 18 |
| 158 | Predicting progression in primary progressive multiple sclerosis: a 10-year multicenter study. *Annals of Neurology*, **2008**, 63, 790-3 | 9.4 | 83 |
| 157 | Will Rogers phenomenon in multiple sclerosis. *Annals of Neurology*, **2008**, 64, 428-33 | 9.4 | 66 |
| 156 | Incorporating domain knowledge into the fuzzy connectedness framework: application to brain lesion volume estimation in multiple sclerosis. *IEEE Transactions on Medical Imaging*, **2007**, 26, 1670-80 | 11.7 | 19 |
| 155 | Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS. *Neurology*, **2007**, 68, 939-44 | 6.5 | 39 |
| 154 | Anton@ syndrome following callosal disconnection. *Behavioural Neurology*, **2007**, 18, 183-6 | 3 | 9 |
| 153 | Intercenter agreement of brain atrophy measurement in multiple sclerosis patients using manually-edited SIENA and SIENAX. *Journal of Magnetic Resonance Imaging*, **2007**, 26, 881-5 | 5.6 | 39 |
| 152 | Diffusion tensor MRI in multiple sclerosis. *Journal of Neuroimaging*, **2007**, 17 Suppl 1, 27S-30S | 2.8 | 52 |
| 151 | MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. *Lancet Neurology, The*, **2007**, 6, 677-86 | 24.1 | 246 |
| 150 | A brain magnetization transfer MRI study with a clinical follow up of about four years in patients with clinically isolated syndromes suggestive of multiple sclerosis. *Journal of Neurology*, **2007**, 254, 78-83 | 5.5 | 15 |
| 149 | Normal-appearing white and grey matter damage in MS. A volumetric and diffusion tensor MRI study at 3.0 Tesla. *Journal of Neurology*, **2007**, 254, 513-8 | 5.5 | 65 |
| 148 | Impaired short-term motor learning in multiple sclerosis: evidence from virtual reality. *Neurorehabilitation and Neural Repair*, **2007**, 21, 273-8 | 4.7 | 42 |
| 147 | Assessing "occult" cervical cord damage in patients with neuropsychiatric systemic lupus erythematosus using diffusion tensor MRI. *Journal of Neurology, Neurosurgery and Psychiatry*, **2007**, 78, 893-5 | 5.5 | 5 |
| 146 | A composite score to predict short-term disease activity in patients with relapsing-remitting MS. *Neurology*, **2007**, 69, 1230-5 | 6.5 | 27 |

| | | | |
|---|---|---|---|
| 145 | Serial whole-brain N-acetylaspartate concentration in healthy young adults. *American Journal of Neuroradiology*, **2007**, 28, 1650-1 | 4.4 | 16 |
| 144 | Determinants of disability in multiple sclerosis at various disease stages: a multiparametric magnetic resonance study. *Archives of Neurology*, **2007**, 64, 1163-8 | | 44 |
| 143 | Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial. *Multiple Sclerosis Journal*, **2007**, 13, 502-8 | 5 | 45 |
| 142 | Diffusion-Weighted Imaging **2007**, 65-74 | | |
| 141 | Secondary progressive multiple sclerosis: current knowledge and future challenges. *Lancet Neurology, The*, **2006**, 5, 343-54 | 24.1 | 206 |
| 140 | MRI and the diagnosis of multiple sclerosis: expanding the concept of "no better explanation". *Lancet Neurology, The*, **2006**, 5, 841-52 | 24.1 | 194 |
| 139 | Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis. *Brain*, **2006**, 129, 2620-7 | 11.2 | 132 |
| 138 | Grey matter damage predicts the evolution of primary progressive multiple sclerosis at 5 years. *Brain*, **2006**, 129, 2628-34 | 11.2 | 111 |
| 137 | Multimodal evoked potentials to assess the evolution of multiple sclerosis: a longitudinal study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2006**, 77, 1030-5 | 5.5 | 114 |
| 136 | Influence of aging on brain gray and white matter changes assessed by conventional, MT, and DT MRI. *Neurology*, **2006**, 66, 535-9 | 6.5 | 101 |
| 135 | MRI markers of destructive pathology in multiple sclerosis-related cognitive dysfunction. *Journal of the Neurological Sciences*, **2006**, 245, 111-6 | 3.2 | 60 |
| 134 | Movement preparation is affected by tissue damage in multiple sclerosis: evidence from EEG event-related desynchronization. *Clinical Neurophysiology*, **2005**, 116, 1515-9 | 4.3 | 19 |
| 133 | Short-term accrual of gray matter pathology in patients with progressive multiple sclerosis: an in vivo study using diffusion tensor MRI. *NeuroImage*, **2005**, 24, 1139-46 | 7.9 | 99 |
| 132 | Mean diffusivity and fractional anisotropy histogram analysis of the cervical cord in MS patients. *NeuroImage*, **2005**, 26, 822-8 | 7.9 | 108 |
| 131 | Glatiramer acetate in multiple sclerosis. *Expert Review of Neurotherapeutics*, **2005**, 5, 451-8 | 4.3 | 3 |
| 130 | Can glatiramer acetate reduce brain atrophy development in multiple sclerosis?. *Journal of the Neurological Sciences*, **2005**, 233, 139-43 | 3.2 | 7 |
| 129 | "Importance sampling": a strategy to overcome the clinical/MRI paradox in MS?. *Journal of the Neurological Sciences*, **2005**, 237, 1-3 | 3.2 | 5 |
| 128 | Mitoxantrone for multiple sclerosis. *Cochrane Database of Systematic Reviews*, **2005**, CD002127 | | 28 |

| | | | |
|---|---|---|---|
| 127 | Axonal injury and overall tissue loss are not related in primary progressive multiple sclerosis. *Archives of Neurology*, **2005**, 62, 898-902 | | 30 |
| 126 | Diffusion-tensor magnetic resonance imaging detects normal-appearing white matter damage unrelated to short-term disease activity in patients at the earliest clinical stage of multiple sclerosis. *Archives of Neurology*, **2005**, 62, 803-8 | | 97 |
| 125 | Immunological patterns identifying disease course and evolution in multiple sclerosis patients. *Journal of Neuroimmunology*, **2005**, 165, 192-200 | 3.5 | 36 |
| 124 | Defining the response to multiple sclerosis treatment: the role of conventional magnetic resonance imaging. *Neurological Sciences*, **2005**, 26 Suppl 4, S204-8 | 3.5 | 7 |
| 123 | Axonal injury in early multiple sclerosis is irreversible and independent of the short-term disease evolution. *Neurology*, **2005**, 65, 1626-30 | 6.5 | 45 |
| 122 | Long-term clinical outcome of primary progressive MS: predictive value of clinical and MRI data. *Neurology*, **2005**, 65, 633-5 | 6.5 | 52 |
| 121 | Evidence for progressive gray matter loss in patients with relapsing-remitting MS. *Neurology*, **2005**, 65, 1126-8 | 6.5 | 69 |
| 120 | Quantification of cervical cord pathology in primary progressive MS using diffusion tensor MRI. *Neurology*, **2005**, 64, 631-5 | 6.5 | 92 |
| 119 | Diffusion MRI in multiple sclerosis. *Neurology*, **2005**, 65, 1526-32 | 6.5 | 222 |
| 118 | Progressive gray matter damage in patients with relapsing-remitting multiple sclerosis: a longitudinal diffusion tensor magnetic resonance imaging study. *Archives of Neurology*, **2005**, 62, 578-84 | | 96 |
| 117 | White Matter Pathology in Systemic Immune-Mediated Diseases **2005**, 343-352 | | |
| 116 | Regional brain atrophy evolves differently in patients with multiple sclerosis according to clinical phenotype. *American Journal of Neuroradiology*, **2005**, 26, 341-6 | 4.4 | 106 |
| 115 | Diffusion imaging in demyelination and inflammation **2004**, 444-459 | | |
| 114 | Imaging primary progressive multiple sclerosis: the contribution of structural, metabolic, and functional MRI techniques. *Multiple Sclerosis Journal*, **2004**, 10 Suppl 1, S36-44; discussion S44-5 | 5 | 22 |
| 113 | The use of magnetic resonance imaging in multiple sclerosis: lessons learned from clinical trials. *Multiple Sclerosis Journal*, **2004**, 10, 341-7 | 5 | 15 |
| 112 | An MT MRI study of the cervical cord in clinically isolated syndromes suggestive of MS. *Neurology*, **2004**, 63, 584-5 | 6.5 | 39 |
| 111 | Diffusion tensor MRI of the cervical cord in a patient with syringomyelia and multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2004**, 75, 1647 | 5.5 | 13 |
| 110 | Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis. *Neurology*, **2004**, 62, 1432-4 | 6.5 | 106 |

| | | | |
|---|---|---|---|
| 109 | Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. *Lancet, The*, **2004**, 364, 1489-96 | 40 | 215 |
| 108 | A new method for analyzing histograms of brain magnetization transfer ratios: comparison with existing techniques. *American Journal of Neuroradiology*, **2004**, 25, 1234-41 | 4.4 | 9 |
| 107 | Beta endorphin concentrations in PBMC of patients with different clinical phenotypes of multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2003**, 74, 495-7 | 5.5 | 13 |
| 106 | The effect of interferon beta-1b on quantities derived from MT MRI in secondary progressive MS. *Neurology*, **2003**, 60, 853-60 | 6.5 | 76 |
| 105 | Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study. *Brain*, **2003**, 126, 2323-32 | 11.2 | 86 |
| 104 | Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. *Brain*, **2003**, 126, 433-7 | 11.2 | 260 |
| 103 | Age-related changes in conventional, magnetization transfer, and diffusion-tensor MR imaging findings: study with whole-brain tissue histogram analysis. *Radiology*, **2003**, 227, 731-8 | 20.5 | 121 |
| 102 | Magnetic resonance-based techniques for the study and management of multiple sclerosis. *British Medical Bulletin*, **2003**, 65, 133-44 | 5.4 | 11 |
| 101 | Occult tissue damage in patients with primary progressive multiple sclerosis is independent of T2-visible lesions--a diffusion tensor MR study. *Journal of Neurology*, **2003**, 250, 456-60 | 5.5 | 45 |
| 100 | Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a. *Annals of Neurology*, **2003**, 53, 718-24 | 9.4 | 96 |
| 99 | A diffusion tensor MRI study of basal ganglia from patients with ADEM. *Journal of the Neurological Sciences*, **2003**, 206, 27-30 | 3.2 | 18 |
| 98 | Whole-brain atrophy in multiple sclerosis measured by two segmentation processes from various MRI sequences. *Journal of the Neurological Sciences*, **2003**, 216, 169-77 | 3.2 | 40 |
| 97 | Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials. *Multiple Sclerosis Journal*, **2003**, 9, 349-55 | 5 | 64 |
| 96 | Somatosensory evoked potentials and sensory involvement in multiple sclerosis: comparison with clinical findings and quantitative sensory tests. *Multiple Sclerosis Journal*, **2003**, 9, 275-9 | 5 | 27 |
| 95 | Interventions for the prevention of brain atrophy in multiple sclerosis : current status. *CNS Drugs*, **2003**, 17, 563-75 | 6.7 | 12 |
| 94 | Short-term correlations between clinical and MR imaging findings in relapsing-remitting multiple sclerosis. *American Journal of Neuroradiology*, **2003**, 24, 75-81 | 4.4 | 20 |
| 93 | Clinical trials and clinical practice in multiple sclerosis: conventional and emerging magnetic resonance imaging technologies. *Current Neurology and Neuroscience Reports*, **2002**, 2, 267-76 | 6.6 | 6 |
| 92 | Magnetic resonance imaging of multiple sclerosis. *Journal of Neuroimaging*, **2002**, 12, 289-301 | 2.8 | 23 |

| | | | |
|---|---|---|---|
| 91 | Two-year follow-up study of primary and transitional progressive multiple sclerosis. *Multiple Sclerosis Journal*, **2002**, 8, 108-14 | 5 | 38 |
| 90 | Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". *Neurology* , **2002**, 58, 1440-1; author reply 1441-2 | 6.5 | 5 |
| 89 | Assessment of normal-appearing white and gray matter in patients with primary progressive multiple sclerosis: a diffusion-tensor magnetic resonance imaging study. *Archives of Neurology*, **2002**, 59, 1406-12 | | 148 |
| 88 | Contribution of cervical cord MRI and brain magnetization transfer imaging to the assessment of individual patients with multiple sclerosis: a preliminary study. *Multiple Sclerosis Journal*, **2002**, 8, 52-8 | 5 | 12 |
| 87 | Frequency and patterns of subclinical cognitive impairment in patients with ANCA-associated small vessel vasculitides. *Journal of the Neurological Sciences*, **2002**, 195, 161-6 | 3.2 | 31 |
| 86 | Effect of glatiramer acetate on MS lesions enhancing at different gadolinium doses. *Neurology*, **2002**, 59, 1429-32 | 6.5 | 25 |
| 85 | Cognitive dysfunction in patients with mildly disabling relapsing-remitting multiple sclerosis: an exploratory study with diffusion tensor MR imaging. *Journal of the Neurological Sciences*, **2002**, 195, 103-9 | 3.2 | 185 |
| 84 | MR-based technology for in vivo detection, characterization, and quantification of pathology of relapsing-remitting multiple sclerosis. *Journal of Rehabilitation Research and Development*, **2002**, 39, 243-59 | | 4 |
| 83 | Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications. *Brain*, **2001**, 124, 1803-12 | 11.2 | 111 |
| 82 | Correlations between clinical findings and magnetization transfer imaging metrics of tissue damage in individuals with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. *Stroke*, **2001**, 32, 643-8 | 6.7 | 52 |
| 81 | Neuroimaging techniques in the diagnostic work-up of patients with the antiphospholipid syndrome. *Current Rheumatology Reports*, **2001**, 3, 301-6 | 4.9 | 3 |
| 80 | Differential diagnosis of posterior fossa multiple sclerosis lesions--neuroradiological aspects. *Neurological Sciences*, **2001**, 22 Suppl 2, S79-83 | 3.5 | 13 |
| 79 | Clinical and MRI assessment of brain damage in MS. *Neurological Sciences*, **2001**, 22 Suppl 2, S123-7 | 3.5 | 11 |
| 78 | Effects of seasons on magnetic resonance imaging measured disease activity in patients with multiple sclerosis. *Annals of Neurology*, **2001**, 49, 415-416 | 9.4 | 27 |
| 77 | Clinical trials of multiple sclerosis monitored with enhanced MRI: new sample size calculations based on large data sets. *Journal of Neurology, Neurosurgery and Psychiatry*, **2001**, 70, 494-9 | 5.5 | 45 |
| 76 | In vivo assessment of the brain and cervical cord pathology of patients with primary progressive multiple sclerosis. *Brain*, **2001**, 124, 2540-9 | 11.2 | 129 |
| 75 | Delivery to the central nervous system of a nonreplicative herpes simplex type 1 vector engineered with the interleukin 4 gene protects rhesus monkeys from hyperacute autoimmune encephalomyelitis. *Human Gene Therapy*, **2001**, 12, 905-20 | 4.8 | 52 |
| 74 | Magnetic resonance imaging, magnetisation transfer imaging, and diffusion weighted imaging correlates of optic nerve, brain, and cervical cord damage in Leber's hereditary optic neuropathy. *Journal of Neurology, Neurosurgery and Psychiatry*, **2001**, 70, 444-9 | 5.5 | 53 |

| | | | |
|---|---|---|---|
| 73 | Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". *Neurology*, **2001**, 57, 731-3 | 6.5 | 247 |
| 72 | Sample size estimations for MRI-monitored trials of MS comparing new vs standard treatments. *Neurology*, **2001**, 57, 1883-5 | 6.5 | 15 |
| 71 | An MR study of tissue damage in the cervical cord of patients with migraine. *Journal of the Neurological Sciences*, **2001**, 183, 43-6 | 3.2 | 28 |
| 70 | The role of non-conventional MR techniques to study multiple sclerosis patients. *Journal of the Neurological Sciences*, **2001**, 186 Suppl 1, S3-9 | 3.2 | 11 |
| 69 | Magnetization transfer and diffusion tensor MR imaging of the optic radiations and calcarine cortex from patients with Leber's hereditary optic neuropathy. *Journal of the Neurological Sciences*, **2001**, 188, 33-6 | 3.2 | 8 |
| 68 | Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. *Lancet, The*, **2001**, 357, 1576-82 | 40 | 884 |
| 67 | Intra-observer, inter-observer and inter-scanner variations in brain MRI volume measurements in multiple sclerosis. *Multiple Sclerosis Journal*, **2001**, 7, 27-31 | 5 | 2 |
| 66 | Modelling new enhancing MRI lesion counts in multiple sclerosis. *Multiple Sclerosis Journal*, **2001**, 7, 298-304 | 5 | 6 |
| 65 | Whole brain volume changes in patients with progressive MS treated with cladribine. *Neurology*, **2000**, 55, 1714-8 | 6.5 | 114 |
| 64 | The value of new magnetic resonance techniques in multiple sclerosis. *Current Opinion in Neurology*, **2000**, 13, 249-54 | 7.1 | 18 |
| 63 | A comparison of the sensitivity of MRI after double- and triple-dose Gd-DTPA for detecting enhancing lesions in multiple sclerosis. *Magnetic Resonance Imaging*, **2000**, 18, 761-3 | 3.3 | 17 |
| 62 | Detection of multiple sclerosis lesions using EPI-FLAIR images. *Magnetic Resonance Imaging*, **2000**, 18, 907-10 | 3.3 | 3 |
| 61 | The contribution of fast-FLAIR MRI for lesion detection in the brain of patients with systemic autoimmune diseases. *Journal of Neurology*, **2000**, 247, 29-33 | 5.5 | 19 |
| 60 | Sensitivity and reproducibility of volume change measurements of different brain portions on magnetic resonance imaging in patients with multiple sclerosis. *Journal of Neurology*, **2000**, 247, 960-5 | 5.5 | 46 |
| 59 | MRI and motor evoked potential findings in nondisabled multiple sclerosis patients with and without symptoms of fatigue. *Journal of Neurology*, **2000**, 247, 506-9 | 5.5 | 97 |
| 58 | One year follow up study of primary and transitional progressive multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2000**, 68, 713-8 | 5.5 | 82 |
| 57 | Relative contributions of brain and cervical cord pathology to multiple sclerosis disability: a study with magnetisation transfer ratio histogram analysis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2000**, 69, 723-7 | 5.5 | 56 |
| 56 | Changes in the normal appearing brain tissue and cognitive impairment in multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2000**, 68, 157-61 | 5.5 | 137 |

| | | | |
|---|---|---|---|
| 55 | Magnetization transfer imaging to monitor the evolution of MS: a 1-year follow-up study. *Neurology*, **2000**, 55, 940-6 | 6.5 | 130 |
| 54 | Electroencephalographic coherence analysis in multiple sclerosis: correlation with clinical, neuropsychological, and MRI findings. *Journal of Neurology, Neurosurgery and Psychiatry*, **2000**, 69, 192-8 | 5.5 | 77 |
| 53 | Brain involvement in systemic immune mediated diseases: magnetic resonance and magnetisation transfer imaging study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2000**, 68, 170-7 | 5.5 | 88 |
| 52 | The effect of cladribine on T(1) ﬁlack holeﬂ changes in progressive MS. *Journal of the Neurological Sciences*, **2000**, 176, 42-4 | 3.2 | 58 |
| 51 | Cervical cord magnetic resonance imaging findings in systemic immune-mediated diseases. *Journal of the Neurological Sciences*, **2000**, 176, 128-30 | 3.2 | 19 |
| 50 | The role of magnetic resonance in the assessment of multiple sclerosis. *Journal of the Neurological Sciences*, **2000**, 172 Suppl 1, S3-S12 | 3.2 | 6 |
| 49 | Assessment of the damage of the cerebral hemispheres in MS using neuroimaging techniques. *Journal of the Neurological Sciences*, **2000**, 172 Suppl 1, S63-6 | 3.2 | 17 |
| 48 | Interferon beta treatment for multiple sclerosis has a graduated effect on MRI enhancing lesions according to their size and pathology. *Journal of Neurology, Neurosurgery and Psychiatry*, **1999**, 67, 386-9 | 5.5 | 17 |
| 47 | Reproducibility of brain MRI lesion volume measurements in multiple sclerosis using a local thresholding technique: effects of formal operator training. *European Neurology*, **1999**, 41, 226-30 | 2.1 | 9 |
| 46 | Correlation between MRI and short-term clinical activity in multiple sclerosis: comparison between standard- and triple-dose Gd-enhanced MRI. *European Neurology*, **1999**, 41, 123-7 | 2.1 | 10 |
| 45 | A longitudinal study comparing the sensitivity of CSE and RARE sequences in detecting new multiple sclerosis lesions. *Magnetic Resonance Imaging*, **1999**, 17, 457-8 | 3.3 | 3 |
| 44 | Correlation between enhancing lesion number and volume on standard and triple dose gadolinium-enhanced brain MRI scans from patients with multiple sclerosis. *Magnetic Resonance Imaging*, **1999**, 17, 985-8 | 3.3 | 7 |
| 43 | Lesion load quantification on fast-FLAIR, rapid acquisition relaxation-enhanced, and gradient spin echo brain MRI scans from multiple sclerosis patients. *Magnetic Resonance Imaging*, **1999**, 17, 1105-10 | 3.3 | 13 |
| 42 | Method for intracellular magnetic labeling of human mononuclear cells using approved iron contrast agents. *Magnetic Resonance Imaging*, **1999**, 17, 1521-3 | 3.3 | 62 |
| 41 | Review neuroimaging in amyotrophic lateral sclerosis. *European Journal of Neurology*, **1999**, 6, 629-37 | 6 | 40 |
| 40 | A comparison of the sensitivity of monthly unenhanced and enhanced MRI techniques in detecting new multiple sclerosis lesions. *Journal of Neurology*, **1999**, 246, 97-106 | 5.5 | 7 |
| 39 | Fatigue and magnetic resonance imaging activity in multiple sclerosis. *Journal of Neurology*, **1999**, 246, 454-8 | 5.5 | 93 |
| 38 | Multiple sclerosis: interobserver agreement in reporting active lesions on serial brain MRI using conventional spin echo, fast spin echo, fast fluid-attenuated inversion recovery and post-contrast T1-weighted images. *Journal of Neurology*, **1999**, 246, 920-5 | 5.5 | 10 |

| | | | |
|---|---|---|---|
| 37 | Short-term evolution of new multiple sclerosis lesions enhancing on standard and triple dose gadolinium-enhanced brain MRI scans. *Journal of the Neurological Sciences*, **1999**, 164, 148-52 | 3.2 | 13 |
| 36 | Brain MRI correlates of magnetization transfer imaging metrics in patients with multiple sclerosis. *Journal of the Neurological Sciences*, **1999**, 166, 58-63 | 3.2 | 25 |
| 35 | Quantitative brain volumetric analysis from patients with multiple sclerosis: a follow-up study. *Journal of the Neurological Sciences*, **1999**, 171, 8-10 | 3.2 | 21 |
| 34 | Cumulative effect of a weekly low dose of interferon beta 1a on standard and triple dose contrast-enhanced MRI from multiple sclerosis patients. *Journal of the Neurological Sciences*, **1999**, 171, 130-4 | 3.2 | 13 |
| 33 | A multiparametric MRI study of frontal lobe dementia in multiple sclerosis. *Journal of the Neurological Sciences*, **1999**, 171, 135-44 | 3.2 | 40 |
| 32 | Magnetic resonance techniques to monitor disease evolution and treatment trial outcomes in multiple sclerosis. *Current Opinion in Neurology*, **1999**, 12, 337-44 | 7.1 | 60 |
| 31 | MRI evolution of new MS lesions enhancing after different doses of gadolinium. *Acta Neurologica Scandinavica*, **1998**, 98, 90-3 | 3.8 | 11 |
| 30 | The effect of repositioning on brain MRI lesion load assessment in multiple sclerosis: reliability of subjective quality criteria. *Journal of Neurology*, **1998**, 245, 273-5 | 5.5 | 16 |
| 29 | How does brain MRI lesion volume change on serial scans in patients with multiple sclerosis?. *Magnetic Resonance Imaging*, **1998**, 16, 1181-3 | 3.3 | 3 |
| 28 | Brain MRI lesion volume measurement reproducibility is not dependent on the disease burden in patients with multiple sclerosis. *Magnetic Resonance Imaging*, **1998**, 16, 1185-9 | 3.3 | 3 |
| 27 | EEG correlates of cognitive impairment in MS. *Italian Journal of Neurological Sciences*, **1998**, 19, S413-S417 | | 2 |
| 26 | A longitudinal brain MRI study comparing the sensitivities of the conventional and a newer approach for detecting active lesions in multiple sclerosis. *Journal of the Neurological Sciences*, **1998**, 159, 94-101 | 3.2 | 9 |
| 25 | Relation between MR abnormalities and patterns of cognitive impairment in multiple sclerosis. *Neurology*, **1998**, 50, 1601-8 | 6.5 | 230 |
| 24 | Magnetization transfer ratios in multiple sclerosis lesions enhancing after different doses of gadolinium. *Neurology*, **1998**, 50, 1289-93 | 6.5 | 71 |
| 23 | Detecting new lesion formation in multiple sclerosis: the relative contributions of monthly dual-echo and T1-weighted scans after triple-dose gadolinium. *European Neurology*, **1998**, 40, 146-50 | 2.1 | 3 |
| 22 | A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials. *Brain*, **1998**, 121 ( Pt 10), 2011-20 | 11.2 | 95 |
| 21 | A preliminary study comparing the sensitivity of serial monthly enhanced MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in primary progressive multiple sclerosis **1998**, 8, 88-93 | | 13 |
| 20 | A comparison between the sensitivities of 3-mm and 5-mm thick serial brain MRI for detecting lesion volume changes in patients with multiple sclerosis **1998**, 8, 144-7 | | 7 |

| | | | |
|---|---|---|---|
| 19 | Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis. *Neurology*, **1997**, 49, 1682-8 | 6.5 | 98 |
| 18 | The influence of slice orientation on brain MRI lesion load measurement in multiple sclerosis. *Multiple Sclerosis Journal*, **1997**, 3, 382-4 | 5 | 0 |
| 17 | A longitudinal magnetic resonance imaging study of the cervical cord in multiple sclerosis **1997**, 7, 78-80 | | 28 |
| 16 | Sensitivity and reproducibility of fast-FLAIR, FSE, and TGSE sequences for the MRI assessment of brain lesion load in multiple sclerosis: a preliminary study **1997**, 7, 98-102 | | 15 |
| 15 | Intra-observer reproducibility in measuring new putative MR markers of demyelination and axonal loss in multiple sclerosis: a comparison with conventional T2-weighted images. *Journal of Neurology* , **1997**, 244, 266-70 | 5.5 | 148 |
| 14 | A comparison of conventional and fast spin-echo sequences for the measurement of lesion load in multiple sclerosis using a semi-automated contour technique. *Neuroradiology*, **1997**, 39, 161-5 | 3.2 | 23 |
| 13 | Semi-automated thresholding technique for measuring lesion volumes in multiple sclerosis: effects of the change of the threshold on the computed lesion loads. *Acta Neurologica Scandinavica*, **1996**, 93, 30-4 | 3.8 | 26 |
| 12 | Pattern visual evoked potential mapping in Alzheimer@ disease: correlations with visuospatial impairment. *Dementia and Geriatric Cognitive Disorders*, **1996**, 7, 63-8 | 2.6 | 7 |
| 11 | Brain MRI follow-up of patients with persistent isolated optic neuritis. *European Journal of Neurology*, **1996**, 3, 36-39 | 6 | 2 |
| 10 | A high-resolution three-dimensional T1-weighted gradient echo sequence improves the detection of disease activity in multiple sclerosis. *Annals of Neurology*, **1996**, 40, 901-7 | 9.4 | 44 |
| 9 | Patterns of disease activity in multiple sclerosis patients: a study with quantitative gadolinium-enhanced brain MRI and cytokine measurement in different clinical subgroups. *Journal of Neurology*, **1996**, 243, 536-42 | 5.5 | 31 |
| 8 | Cardiac autonomic function during sleep and wakefulness in multiple sclerosis. *Journal of Neurology*, **1995**, 242, 639-43 | 5.5 | 19 |
| 7 | Acute myelopathy of unknown aetiology: a clinical, neurophysiological and MRI study of short- and long-term prognostic factors. *Journal of Neurology*, **1995**, 242, 497-503 | 5.5 | 25 |
| 6 | Nocturnal sleep study in multiple sclerosis: correlations with clinical and brain magnetic resonance imaging findings. *Journal of the Neurological Sciences*, **1994**, 125, 194-7 | 3.2 | 132 |
| 5 | Brain magnetic resonance imaging correlates of cognitive impairment in multiple sclerosis. *Journal of the Neurological Sciences*, **1993**, 115 Suppl, S66-73 | 3.2 | 76 |
| 4 | Brain stem magnetic resonance imaging and evoked potential studies of symptomatic multiple sclerosis patients. *European Neurology*, **1993**, 33, 232-7 | 2.1 | 25 |
| 3 | Diffusion and perfusion MRI in inflammation and demyelination488-500 | | |
| 2 | A theory of mind training for people with multiple sclerosis: Development of a scale to assess the treatment acceptability. *Current Psychology*,1 | 1.4 | |

# List of Publications

1 Magnetic resonance imaging to study white matter damage in multiple sclerosis79-85